VA
GMAB icon

Vident Advisory’s Genmab GMAB Stock Holding History

Vident Advisory’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Sell
44,400
-3,979
-8% -$106K 0.01% 879
2026
Q1 		$1.3M Buy
48,379
+8,672
+22% +$260K 0.01% 768
2025
Q4 		$1.22M Buy
39,707
+4,060
+11% +$127K 0.01% 723
2025
Q3 		$1.09M Buy
35,647
+4,165
+13% +$101K 0.01% 789
2025
Q2 		$650K Buy
31,482
+19,105
+154% +$392K 0.01% 909
2025
Q1 		$242K Buy
+12,377
New +$260K ﹤0.01% 1351
2024
Q4 		– Sell
-8,388
Closed -$205K – 1487
2024
Q3 		$205K Buy
+8,388
New +$224K 0.01% 1314
2023
Q4 		– Sell
-8,262
Closed -$291K – 1341
2023
Q3 		$291K Buy
+8,262
New +$315K 0.01% 924

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vident Advisory's GMAB Position: Q2 2026 in Review

Vident Advisory reduced its Genmab (GMAB) stake by 8.2% in Q2 2026, selling an estimated $106K and leaving 44,400 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #879.

Vident Advisory first reported a position in GMAB in Q3 2023 and has held it in 8 quarters since. The position peaked at $1.3M in Q1 2026. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Vident Advisory held 44,400 shares of Genmab worth $1.22M as of Q2 2026.
  • Vident Advisory sold 3,979 Genmab shares in Q2 2026, an estimated $106K.
  • Genmab made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #879 holding.
  • Vident Advisory first reported a position in Genmab in Q3 2023 and has held it in 8 quarters since.
  • Vident Advisory's Genmab position peaked at $1.3M in Q1 2026.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.